Mesenchymal Stem Cell Transplantation for the Treatment of Age-Related Musculoskeletal Frailty

International Journal of Molecular Sciences

Min Hwei Ng¹  Fazlina Nordin¹  Elancheleyen Mahindran¹  Jia Xian Law¹ 

[1] Centre for Tissue Engineering and Regenerative Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif,Kuala Lumpur 56000, Cheras, Malaysia;

关键词: mesenchymal stem cells;    aging;    frailty;    musculoskeletal system;    bone;    muscle;   

DOI  :  10.3390/ijms221910542

来源: DOAJ

【 摘 要 】

Projected life expectancy continues to grow worldwide owing to the advancement of new treatments and technologies leading to rapid growth of geriatric population. Thus, age-associated diseases especially in the musculoskeletal system are becoming more common. Loss of bone (osteoporosis) and muscle (sarcopenia) mass are conditions whose prevalence is increasing because of the change in population distribution in the world towards an older mean age. The deterioration in the bone and muscle functions can cause severe disability and seriously affects the patients’ quality of life. Currently, there is no treatment to prevent and reverse age-related musculoskeletal frailty. Existing interventions are mainly to slow down and control the signs and symptoms. Mesenchymal stem cell (MSC) transplantation is a promising approach to attenuate age-related musculoskeletal frailty. This review compiles the present knowledge of the causes and changes of the musculoskeletal frailty and the potential of MSC transplantation as a regenerative therapy for age-related musculoskeletal frailty.

【 授权许可】

Unknown